John M. Davis, MD

  • 17Articles
  • 61.4KReads
  • 1997–2025Active
  • 68Collaborators
  • 199Citations

About

John M. Davis, MD, is affiliated with the Department of Psychiatry at the University of Illinois in Chicago. He has contributed 17 articles to Psychiatrist.com between 1997 and 2025, focusing on topics such as schizophrenia, schizoaffective disorders, bipolar disorder, complementary and alternative medicine, metabolic disorders, and violence and aggression. Frequent collaborators include Christopher E. Ramsden, Ira D. Glick, Alan J. Gelenberg, Daisy Zamora, and David S. Janowsky.

Publications

JCP
Sulforaphane Added to Antipsychotics for Negative Symptoms of Schizophrenia
Original Research

Sulforaphane Added to Antipsychotics for Negative Symptoms of Schizophrenia

January 20, 2025

Add-on high dose sulforaphane may reduce negative symptoms in patients with schizophrenia, although the clinical significance of this reduction needs further evaluation.
, , , et al
JCP
Add-on Pramipexole for Schizophrenia
Original Research

Add-on Pramipexole for Schizophrenia

August 1, 2022

Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. This 16-week, multicenter, double-blind, randomized, placebo-controlled study was conducted to test...
, , , et al
JCP
Original Research

Raloxifene in Postmenopausal Women With Schizophrenia

August 23, 2017

The estrogen protection hypothesis of schizophrenia was introduced in the late 1980s to explain  gender-related differences in epidemiology and clinical features. This study examines whether raloxifene, an estrogen agonist,...
, , , et al
JCP
Review Article

Polyunsaturated Fatty Acids in Bipolar Disorder

October 26, 2016

Considering omega-3 and omega-6 fatty acids to supplement bipolar treatment? Read this review article for the latest evidence on this promising treatment strategy.
, , , et al
JCP
Commentary

Reconsidering Dietary Polyunsaturated Fatty Acids in Bipolar Disorder

October 26, 2016

This commentary by Erika F. H. Saunders and colleagues discusses the findings in their article "Omega-3 and Omega-6 Polyunsaturated Fatty Acids in Bipolar Disorder: A Review of Biomarker and...
, , , et al
JCP
Commentary

The Incidence of Seizures With Antipsychotics

May 25, 2016

JCP
Commentary

Do Antipsychotics Cause Hip Fractures? Promise and Pitfalls of Big Data

September 23, 2015

,
JCP
Original Research

Antipsychotic Medications & Schizophrenia

December 15, 2011

Explore an analysis on Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia.
, , , et al
JCP
Original Research

Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic Treatment: A Randomized 5-Month Study

October 6, 2009

, , , et al
JCP
Letter to the Editor

Treating Schizophrenia With Comorbid Depressive or Demoralization Symptoms

March 14, 2008

, ,
JCP
Original Research

Omega-3 Fatty Acids: Evidence Basis for Treatment and Future Research in Psychiatry

December 15, 2006

, , , et al
JCP
Original Research

Concomitant Medications May Not Improve Outcome of Antipsychotic Monotherapy for Stabilized Patients With Nonacute Schizophrenia.

August 15, 2006

, ,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe